Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

This study has been completed.

First Received on September 12, 2005. Last Updated on May 25, 2007 History of Changes

Sponsor:	Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:	Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:	NCT00195208

Purpose

The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.

Condition	Intervention	Phase
Gastroesophageal Reflux Esophagitis	Drug: Pantoprazole for approximately 9 weeks	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis.

Resource links provided by NLM:

MedlinePlus related topics: GERD

Drug Information available for: Pantoprazole Pantoprazole Sodium

U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:

Comparison of MAO between the two formulations.

Secondary Outcome Measures:

Comparison of BAO and pH parameters between the two formulations.

Estimated Enrollment:	65
Study Start Date:	July 2005

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

GERD and a history of Erosive Esophagitis documented by endoscopy
H. pylori negative

Exclusion Criteria:

Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous vagotomy
Achlorhydria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00195208

Locations

United States, California

Anaheim, California, United States, 92801

Los Angeles, California, United States, 90073

Orange, California, United States, 92869

San Diego, California, United States, 92103
United States, Florida

Miami, Florida, United States, 33173
United States, Oklahoma

Oklahoma City, Oklahoma, United States, 73104

Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Philadelphia, Pennsylvania, United States, 19140

Sponsors and Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

Study Director:

Medical Monitor

Wyeth is now a wholly owned subsidiary of Pfizer

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00195208 History of Changes
Other Study ID Numbers:	3001B1-332
Study First Received:	September 12, 2005
Last Updated:	May 25, 2007
Health Authority:	United States: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Gastroesophageal Reflux Disease (GERD)

Additional relevant MeSH terms:

Esophagitis
Gastroesophageal Reflux
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Esophageal Motility Disorders
Deglutition Disorders

Pantoprazole
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012